Skip to main content

Table 2 Number of positive questionnaire answers and autoantibodies among controls and subjects with undifferentiated connective tissue disease, major rheumatic diseases and no criteria for diagnosis

From: The impact of unrecognized autoimmune rheumatic diseases on the incidence of preeclampsia and fetal growth restriction: a longitudinal cohort study

 

Controls n = 597

UCTD n = 131

Major rheumatic diseases n = 68

No criteria for diagnosis n = 150

N. of items

N (%)

N (%)

N (%)

N (%)

 1

-

8 (61.1)

8 (11.8)

-

 2

-

54 (41.2)

24 (35.3)

87 (58)

 >2

-

69 (52.7)

36 (52.9)

63 (42)

ANA titre

 1:80

24 (4)

42 (32.1)

13 (19.1)

82 (54.6)

 1:160

8 (1.3)

46 (35.1)

16 (23.5)

26 (17.3)

  > 1:160

 

43 (32.8)

26 (38.2)

11 (7.3)

dsDNA

0

5 (3.8)

8 (11.7)

2 (1.3)

ENA

0

17 (12.9)

22 (32.4)

0

aCLIgG

0

6 (4.6)

10 (14.7)

9 (6)

aCL IgM

1 (0.16)

14 (10.7)

11 (16.2)

22 (14.6)

beta2GP1IgG

0

4 (3.05)

8 (11.7)

8 (5.3)

LAC

0

1 (0.76)

9 (13.2)

0

  1. UCTD undifferentiated connective tissue disease, ANA antinuclear antibodies, dsDNA anti-double stranded DNA, ENA extractable nuclear antigen antibodies, aCL anticardiolipin autoantibodies, beta2GP1 beta2glicoprotein1, LAC lupus anticoagulant